```html

Nigu (Nigerian) Fever – Comprehensive Medical Guide

Overview

Nigu fever (sometimes spelled nigu or referred to as “Nigerian fever”) is a colloquial term used in parts of Nigeria for an acute, febrile illness that is most commonly caused by Plasmodium falciparum malaria, but can also result from other infectious agents such as dengue virus, typhoid fever, or viral hemorrhagic fevers. Because the term is not a formal medical diagnosis, it is often used by patients and community health workers to describe any high‑grade fever accompanied by chills, rigors, and systemic symptoms.

The condition predominantly affects:

• Children under 5 years of age (who have the highest malaria mortality)
• Pregnant women (increased risk of severe malaria and adverse pregnancy outcomes)
• Rural populations with limited access to clean water, insect‑proof housing, and health services

According to the World Health Organization (WHO), Nigeria accounts for ≈ 25 % of global malaria cases and 20 % of malaria deaths, translating to roughly 56 million cases and 140 000 deaths per year (WHO, 2023). While not all of these are labeled “Nigu,” the term captures a large share of those febrile illnesses.

Symptoms

Because Nigu fever can stem from several pathogens, the symptom picture varies. The most frequently reported cluster—typical of malaria‑related Nigu—includes:

• Fever – sudden onset, often >38.5 °C (101.3 °F); may be intermittent (every 48‑72 h) or continuous.
• Chills and rigors – intense shivering episodes that precede the fever spike.
• Headache – dull to throbbing, sometimes described as “brain fever.”
• Muscle and joint pain – generalized aching, especially in the back and limbs.
• Fatigue and malaise – profound tiredness that can last weeks after the acute phase.
• Nausea, vomiting, or loss of appetite.
• Abdominal discomfort – may mimic gastro‑intestinal infection.
• Sweating – profuse sweating after the fever peaks.
• Enlarged spleen or liver – palpable in chronic or severe cases.

When Nigu fever is caused by other agents, additional signs may appear:

• Dengue‑related Nigu – rash, retro‑orbital pain, severe bruising or bleeding.
• Typhoid‑related Nigu – rose‑colored spots on the trunk (rose spots), constipation or diarrhoea, bradycardia.
• Viral hemorrhagic fevers (e.g., Lassa fever) – bleeding from gums, petechiae, neck stiffness.

Causes and Risk Factors

Primary infectious agents

1. Plasmodium falciparum malaria – transmitted by the bite of an infected Anopheles mosquito. This is the most common cause of “Nigu” in endemic zones.
2. Dengue virus – spread by Aedes aegypti mosquitoes; outbreaks have risen in urban Nigerian centers.
3. Salmonella Typhi (typhoid fever) – via contaminated water or food.
4. Lassa virus – rodent‑borne hemorrhagic fever, especially in northern Nigeria.
5. Other causes – influenza, bacterial sepsis, or non‑infectious fever (e.g., autoimmune disease) can be mis‑identified as Nigu.

Key risk factors

• Geographic exposure – living in or visiting malaria‑endemic states such as Kano, Benin, or Delta.
• Seasonality – rainy season (April–October) fuels mosquito breeding.
• Poor housing – lack of screened windows, no bed nets.
• Limited access to preventive health services – no regular antenatal care, no indoor residual spraying.
• Immunocompromised status – HIV infection, malnutrition, or chronic disease.
• Pregnancy – altered immunity increases susceptibility to severe malaria.

Diagnosis

Because “Nigu fever” is a descriptive term, clinicians first determine the underlying pathogen. The diagnostic work‑up includes:

1. Clinical assessment

• History of travel, exposure to mosquitoes, water source, and vaccination status.
• Physical exam focusing on temperature, vital signs, spleen size, rash, and signs of dehydration.

2. Laboratory tests

1. Rapid Diagnostic Test (RDT) for malaria – detects P. falciparum HRP2 antigen; results in 15 minutes. Sensitivity >95 % in high‑parasitemia settings (WHO, 2022).
2. Peripheral blood smear (thick & thin) – gold standard; quantifies parasitemia and identifies species.
3. Dengue NS1 antigen or IgM/IgG serology – useful during the first 5 days of illness.
4. Blood culture – for suspected typhoid or bacterial sepsis.
5. Lassa virus PCR – reserved for patients with hemorrhagic signs and epidemiologic link.
6. Complete blood count (CBC) – looks for anemia, thrombocytopenia, leukopenia.
7. Liver and renal panels – baseline organ function before starting certain antimalarials.

3. Imaging (if indicated)

• Chest X‑ray for pneumonia overlap.
• Abdominal ultrasound to assess hepatosplenomegaly.

Treatment Options

Treatment hinges on the identified pathogen. Below are evidence‑based regimens endorsed by the WHO and national Nigerian guidelines.

1. Uncomplicated Plasmodium falciparum malaria

• Artemisinin‑based Combination Therapy (ACT) – first‑line in Nigeria.
  • Artemether‑Lumefantrine (Coartem) – 6‑dose regimen over 3 days.
  • Alternatives: Artesunate‑Amodiaquine, Dihydroartemisinin‑Piperaquine.
• Supportive care – antipyretics (paracetamol 500 mg q6h), oral rehydration salts (ORS), and nutrition.

2. Severe malaria (e.g., cerebral involvement, organ failure)

• Intravenous artesunate 2.4 mg/kg at 0, 12, and 24 h, then daily until able to switch to oral ACT.
• Manage complications: blood transfusion for severe anemia, renal replacement therapy if needed, seizure control with diazepam.
• Admit to an intensive care or high‑dependency unit.

3. Dengue fever

• No specific antiviral; focus on fluid management to avoid both dehydration and fluid overload.
• Acetaminophen for pain/fever (avoid NSAIDs due to bleeding risk).
• Hospitalization if warning signs (see below) develop.

4. Typhoid fever

• First‑line: Ceftriaxone 2 g IV daily for 10–14 days OR Azithromycin 1 g PO once, then 500 mg daily for 6 days (per CDC 2023).
• Fluoroquinolones (e.g., ciprofloxacin) only if susceptibility confirmed.

5. Lassa fever (rare but serious)

• Ribavirin 30 mg/kg loading dose, then 16 mg/kg every 6 h for 4 days, then 8 mg/kg every 8 h for 6 days.
• Strict isolation and contact precautions.

Supportive measures for all forms

• Hydration – ORS or IV fluids as needed.
• Antipyretics – paracetamol preferred.
• Nutritional support – high‑protein diet, micronutrient supplementation (e.g., folic acid, vitamin A).
• Education on completing the full medication course to prevent resistance.

Living with Nigu (Nigerian) Fever

Even after successful treatment, many patients experience lingering fatigue or recurrent bouts, especially in high‑transmission zones.

Daily management tips

• Adhere to medication schedules – use a pillbox or mobile alarm.
• Maintain hydration – at least 2 L of fluid daily; incorporate soups and fruit juices.
• Use insecticide‑treated bed nets (ITNs) every night, even if you feel well.
• Screen windows and doors – install fine mesh screens to keep mosquitoes out.
• Monitor temperature – keep a simple thermometer; record any spikes >38 °C.
• Attend follow‑up appointments – repeat blood smear 24–48 h after treatment to confirm parasite clearance.
• Nutrition – iron‑rich foods (leafy greens, beans) to rebuild hemoglobin; vitamin C to aid iron absorption.
• Avoid self‑medication – especially herbal remedies that may interfere with antimalarials.

Psychosocial aspects

Repeated febrile episodes can cause anxiety and affect school or work attendance. Community health education, peer support groups, and counseling can improve adherence and quality of life.

Prevention

Because most cases of Nigu fever are mosquito‑borne, vector control is the cornerstone of prevention.

Personal protective measures

• Sleep under ITNs treated with long‑acting insecticide (replace every 3 years).
• Apply EPA‑approved repellents containing DEET, picaridin, or IR3535 on exposed skin.
• Wear long‑sleeved shirts and trousers during dusk‑to‑dawn hours.

Environmental interventions

• Eliminate standing water (discard old tires, clean gutters) to reduce mosquito breeding sites.
• Participate in community “larvicide” spraying programs.
• Support indoor residual spraying (IRS) campaigns in high‑risk villages.

Pharmacologic prophylaxis

• Seasonal malaria chemoprevention (SMC) – for children 3–59 months during peak transmission (sulphadoxine‑pyrimethamine + amodiaquine, once monthly).
• Pregnant women in the second and third trimesters should receive intermittent preventive treatment with sulfadoxine‑pyrimethamine (IPTp‑SP) as per WHO guidelines.

Vaccination

• RTS,S/AS01 (Mosquirix) – malaria vaccine approved by WHO for children in high‑transmission areas; 4‑dose schedule reduces clinical malaria by ~30 %.
• Dengue vaccine (TAK‑003) is under evaluation in Nigeria; future implementation could further lower dengue‑related Nigu cases.

Complications

If left untreated or inadequately treated, Nigu fever can progress to serious complications, many of which are life‑threatening.

• Severe malaria – cerebral malaria, acute respiratory distress syndrome (ARDS), severe anemia, hypoglycemia, renal failure.
• Dengue shock syndrome – plasma leakage leading to hypotension.
• Typhoid intestinal perforation – requires emergency surgery.
• Lassa hemorrhagic fever – multi‑organ failure.
• Secondary bacterial infections – due to immune suppression.
• Pregnancy loss – miscarriage, stillbirth, or pre‑term delivery in pregnant women with malaria.

When to Seek Emergency Care

References

• World Health Organization. World Malaria Report 2023. Accessed April 2026.
• Mayo Clinic. Malaria: Symptoms & Causes. Accessed April 2026.
• Centers for Disease Control and Prevention. Typhoid Fever. Updated 2023.
• Cleveland Clinic. Dengue Fever. Accessed April 2026.
• National Institute of Allergy and Infectious Diseases (NIH). Lassa Fever. Updated 2023.
• WHO. Insecticide‑treated nets. 2022.
• WHO. RTS,S/AS01 malaria vaccine. 2022.

```